NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.
The investigation concerns whether Emergent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 31, 2021, the New York Times published an article reporting on the accidental contamination at an Emergent manufacturing plant in Baltimore of coronavirus vaccines developed by Johnson & Johnson and AstraZeneca PLC. According to reporting by the Associated Press, the Emergent factory where the contamination occurred had a series of lapses observed by the U.S. Food and Drug Administration in April 2020.
On this news, Emergent’s stock price fell $12.45 per share, or 13.4%, to close at $80.46 per share on April 1, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com